Literature DB >> 1899447

Ribose facilitates thallium-201 redistribution in patients with coronary artery disease.

N S Perlmutter1, R A Wilson, D A Angello, R T Palac, J Lin, B G Brown.   

Abstract

To investigate whether i.v. infusion of ribose, an adenine nucleotide precursor, postischemia facilitates thallium-201 (201Tl) redistribution and improves identification of ischemic myocardium in patients with coronary artery disease (CAD), 17 patients underwent two exercise 201Tl stress tests, performed 1-2 wk apart. After immediate postexercise planar imaging, patients received either i.v. ribose (3.3 mg/kg/min x 30 min) or saline as a control. Additional imaging was performed 1 and 4 hr postexercise. Reversible defects were identified by count-profile analysis. Significantly more (nearly twice as many) reversible 201Tl defects were identified on the post-ribose images compared to the post-saline (control) images at both 1 and 4 hr postexercise (p less than 0.001). Quantitative analyses of the coronary arteriogram was available in 13 patients and confirmed that the additional reversible defects were in myocardial regions supplied by stenosed arteries. We conclude that ribose appears to facilitate 201Tl redistribution in patients with CAD and enhances identification of ischemic myocardium.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1899447

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  9 in total

1.  D-ribose aids heart failure patients with preserved ejection fraction and diastolic dysfunction: a pilot study.

Authors:  Melike Bayram; J A St Cyr; William T Abraham
Journal:  Ther Adv Cardiovasc Dis       Date:  2015-02-19

2.  Acipimox does not augment thallium-201 redistribution in the fasting state.

Authors:  M G Gunning; G Clunie; S Yepes-Mora; S Eastick; S R Underwood; J Bomanji; P J Ell
Journal:  J Nucl Cardiol       Date:  1999 Nov-Dec       Impact factor: 5.952

3.  Effects of therapeutic ribose levels on human lymphocyte proliferation in vitro.

Authors:  W Pliml; T von Arnim; C Hammer
Journal:  Clin Investig       Date:  1993-10

4.  The oxidative pentose phosphate pathway in the heart: regulation, physiological significance, and clinical implications.

Authors:  H G Zimmer
Journal:  Basic Res Cardiol       Date:  1992 Jul-Aug       Impact factor: 17.165

5.  Selective intracoronary injection of sestamibi to detect myocardial viability: Prediction of perfusion and contractile recovery after percutaneous transluminal coronary angioplasty.

Authors:  Carlo Trani; Alessandro Giordano; Antonella Lombardo; Alessandro Lupi; Francesca Reale; Roberto Patrizi; Giampiero Patrizi; Mario A Mazzari; Giovanni Schiavoni; Attilio Maseri
Journal:  J Nucl Cardiol       Date:  2003 Sep-Oct       Impact factor: 5.952

6.  Pharmacokinetic evaluation of D-ribose after oral and intravenous administration to healthy rabbits.

Authors:  Karem H Alzoubi; Zuhair Bani Ismail; Mohamed K Al-Essa; Osama Y Alshogran; Reem F Abutayeh; Nareman Abu-Baker
Journal:  Clin Pharmacol       Date:  2018-06-12

7.  D-Ribose Induces Podocyte NLRP3 Inflammasome Activation and Glomerular Injury via AGEs/RAGE Pathway.

Authors:  Jinni Hong; Guangbi Li; Qinghua Zhang; Joseph Ritter; Weiwei Li; Pin-Lan Li
Journal:  Front Cell Dev Biol       Date:  2019-10-30

8.  Gavage of D-Ribose induces Aβ-like deposits, Tau hyperphosphorylation as well as memory loss and anxiety-like behavior in mice.

Authors:  Beibei Wu; Yan Wei; Yujing Wang; Tao Su; Lei Zhou; Ying Liu; Rongqiao He
Journal:  Oncotarget       Date:  2015-10-27

Review 9.  Potential Clinical Benefits of D-ribose in Ischemic Cardiovascular Disease.

Authors:  Linda M Shecterle; Kathleen R Terry; John A St Cyr
Journal:  Cureus       Date:  2018-03-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.